title: Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer.
abstract: BACKGROUND
  To clarify the tolerance and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic or recurrent breast cancer.
  
  
  METHODS
  From January 2008 through to September 2009, combined therapy with S-1 and trastuzumab was given to 7 patients with HER2-positive metastatic or recurrent breast cancer. The incidence of adverse events and the pharmacokinetics of tegafur, 5-fluorouracil, and gimeracil in plasma were studied.
  
  
  RESULTS
  One patient had grade 3 leukopenia, and another had a grade 3 elevation of alanine aminotransferase. All other adverse events were grade 2 or lower. The combination of S-1 and trastuzumab did not cause any new adverse events. The incidence of adverse events was similar to those associated with S-1 alone. The median number of treatment cycles was 11. The pharmacokinetics of tegafur, 5-fluorouracil, and gimeracil after treatment with S-1 plus trastuzumab did not markedly differ from those after S-1 alone.
  
  
  CONCLUSIONS
  Combined therapy with S-1 and trastuzumab did not cause any new adverse events, administration continuity was good, and the therapy was well tolerated.
authors.affiliation: Division of Breast and Endocrine Surgery, Department of Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan, luke-szk@is.icc.u-tokai.ac.jp.
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Rin
authors.initials: R
authors.lastname: Ogiya
authors.forename: Risa
authors.initials: R
authors.lastname: Oshitanai
authors.forename: Mayako
authors.initials: M
authors.lastname: Terao
authors.forename: Mizuho
authors.initials: M
authors.lastname: Terada
authors.forename: Toru
authors.initials: T
authors.lastname: Morioka
authors.forename: Banri
authors.initials: B
authors.lastname: Tsuda
authors.forename: Naoki
authors.initials: N
authors.lastname: Niikura
authors.forename: Takuho
authors.initials: T
authors.lastname: Okamura
authors.forename: Yuki
authors.initials: Y
authors.lastname: Saito
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Tokuda
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000737:chemistry / Q000188:drug therapy* / Q000473:pathology; D004338:Drug Combinations; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000737:chemistry / Q000188:drug therapy*; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D004338:Drug Combinations; D010094:Oxonic Acid; D018719:Erb-b2 Receptor Tyrosine Kinases; D005641:Tegafur; D000068878:Trastuzumab; C079198:S 1 (combination); C508053:ERBB2 protein, human
references.citation: Breast Cancer. 2004;11(2):194-202
references.pmid: 15550867
references.citation: Clin Breast Cancer. 2009 Feb;9(1):16-22
references.pmid: 19299235
references.citation: Br J Cancer. 2005 Oct 17;93(8):884-9
references.pmid: 16189518
references.citation: N Engl J Med. 1998 Oct 1;339(14):974-84
references.pmid: 9753714
references.citation: J Clin Oncol. 2003 Nov 1;21(21):3965-71
references.pmid: 14507946
references.citation: Clin Cancer Res. 1999 Aug;5(8):2000-5
references.pmid: 10473078
references.citation: Ann Oncol. 2003 Aug;14(8):1222-6
references.pmid: 12881383
references.citation: Lung Cancer. 2004 Apr;44(1):99-110
references.pmid: 15013588
references.citation: J Clin Oncol. 1998 Oct;16(10):3439-60
references.pmid: 9779724
references.citation: Anticancer Drugs. 2008 Aug;19(7):753-9
references.pmid: 18594220
references.citation: J Clin Oncol. 1996 Aug;14(8):2197-205
references.pmid: 8708708
references.citation: Anticancer Res. 2011 Sep;31(9):3035-9
references.pmid: 21868555
references.citation: Jpn J Clin Oncol. 2011 Sep;41(9):1051-8
references.pmid: 21810868
references.citation: Gan To Kagaku Ryoho. 1998 Jun;25(7):1035-43
references.pmid: 9644319
references.citation: J Pharmacokinet Pharmacodyn. 2003 Aug;30(4):257-83
references.pmid: 14650374
references.citation: Cancer. 1982 Mar 1;49(5):835-9
references.pmid: 7037152
references.citation: J Chromatogr B Biomed Sci Appl. 1997 Mar 28;691(1):95-104
references.pmid: 9140762